{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:41:41Z","timestamp":1782337301841,"version":"3.54.5"},"reference-count":35,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mantle cell lymphoma (MCL) is an incurable subtype of B-cell non-Hodgkin lymphoma. Despite multiple approved Bruton tyrosine kinase inhibitors (BTKis), resistance to BTKi continues to pose a major clinical challenge. The transcription factor sex determining region Y-box 11 (SOX11) is expressed in most patients with MCL and is associated with poor outcomes. We have previously demonstrated SOX11-dependent B-cell receptor (BCR) signaling in transgenic models of MCL. Here, we report that SOX11 drives BCR signaling via the transcriptional activation of the PAX5\/CD19 axis. The translational potential of these results is significant as single-cell RNA sequencing data show that SOX11 is overexpressed in ibrutinib-resistant patients as compared to ibrutinib-sensitive patients. Treatment with the SOX11 DNA-binding inhibitor (SOX11i) significantly reduces the expression of PAX5, CD19, and components of BCR signaling in both ibrutinib-sensitive and ibrutinib-resistant cell lines. Importantly, SOX11i was able to demonstrate cytotoxicity in cells derived from ibrutinib-resistant, venetoclax (B-cell lymphoma 2 [BCL2] inhibitor), and chimeric antigen receptor T-cell\u2013resistant patient-derived xenograft models in vitro. SOX11i treatment reduced the tumor growth in vivo in an MCL xenograft model without any significant toxicity. SOX11 inhibition offers significant potential for patients with MCL, especially BTKi-resistant patients, by targeting upstream resistance mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016801","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:00:27Z","timestamp":1755892827000},"page":"6267-6278","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["SOX11 modulates BCR signaling through the PAX5\/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-0151","authenticated-orcid":false,"given":"Rudra Prasad","family":"Dutta","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, The Tisch Cancer Institute, The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-1292","authenticated-orcid":false,"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-0601","authenticated-orcid":false,"given":"Violetta V.","family":"Leshchenko","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, The Tisch Cancer Institute, The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7492-5848","authenticated-orcid":false,"given":"Ravi Prakash","family":"Shukla","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, The Tisch Cancer Institute, The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-8076","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5327-832X","authenticated-orcid":false,"given":"H. \u00dcmit","family":"Kaniskan","sequence":"additional","affiliation":[{"name":"3Department of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Mount Sinai Center for Therapeutics Discovery, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Qiu","sequence":"additional","affiliation":[{"name":"3Department of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Mount Sinai Center for Therapeutics Discovery, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-3862","authenticated-orcid":false,"given":"Jian","family":"Jin","sequence":"additional","affiliation":[{"name":"3Department of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Mount Sinai Center for Therapeutics Discovery, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-8469","authenticated-orcid":false,"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, The Tisch Cancer Institute, The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"8","key":"2025122309511278100_bib1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"issue":"16","key":"2025122309511278100_bib2","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-20-5039","article-title":"SOX11 inhibitors are cytotoxic in mantle cell lymphoma","volume":"27","author":"Jatiani","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025122309511278100_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025122309511278100_bib4","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1038\/s41598-024-55728-9","article-title":"B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression","volume":"14","author":"Gambino","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"2025122309511278100_bib5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2025122309511278100_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1586\/ehm.12.21","article-title":"Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia","volume":"5","author":"Scupoli","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2025122309511278100_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2025122309511278100_bib8","first-page":"1","article-title":"New directions for mantle cell lymphoma in 2022","volume":"42","author":"Kumar","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"2025122309511278100_bib9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022\u2014a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"2025122309511278100_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41419-017-0157-6","article-title":"CD40L mediated alternative NF\u03baB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma","volume":"9","author":"Rauert-Wunderlich","year":"2018","journal-title":"Cell Death Dis"},{"key":"2025122309511278100_bib11","doi-asserted-by":"crossref","first-page":"591577","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front Oncol"},{"issue":"20","key":"2025122309511278100_bib12","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1182\/bloodadvances.2023009906","article-title":"PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma","volume":"7","author":"Brown-Burke","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2025122309511278100_bib13","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/onc.2014.44","article-title":"High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma","volume":"34","author":"Kuo","year":"2015","journal-title":"Oncogene"},{"issue":"19","key":"2025122309511278100_bib14","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.2023022241","article-title":"SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma","volume":"143","author":"Abdelrazak Morsy","year":"2024","journal-title":"Blood"},{"issue":"20","key":"2025122309511278100_bib15","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood-2018-02-832535","article-title":"SOX11 augments BCR signaling to drive MCL-like tumor development","volume":"131","author":"Kuo","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2025122309511278100_bib16","doi-asserted-by":"crossref","first-page":"e165694","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"issue":"2","key":"2025122309511278100_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1535-7163.MCT-18-0478","article-title":"Pleiotropic action of novel Bruton\u2019s tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2025122309511278100_bib18","first-page":"1102","article-title":"PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma","volume":"12","author":"Huang","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"4","key":"2025122309511278100_bib19","doi-asserted-by":"crossref","first-page":"100049","DOI":"10.1016\/j.bneo.2024.100049","article-title":"Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma","volume":"1","author":"Dutta","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"1","key":"2025122309511278100_bib20","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","article-title":"Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2025122309511278100_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-024-00484-9","article-title":"The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma","volume":"13","author":"Yan","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"S2","key":"2025122309511278100_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/hon.2438_65","article-title":"Long-term follow-up update for patients enrolled in ECOG 1405","volume":"35","author":"Khan","year":"2017","journal-title":"Hematol Oncol"},{"issue":"1","key":"2025122309511278100_bib23","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"2025122309511278100_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","article-title":"Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules","volume":"20","author":"Henley","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"6625","key":"2025122309511278100_bib25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/386569a0","article-title":"Transcriptional activation by recruitment","volume":"386","author":"Ptashne","year":"1997","journal-title":"Nature"},{"issue":"1","key":"2025122309511278100_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41420-024-01834-6","article-title":"SOX on tumors, a comfort or a constraint?","volume":"10","author":"Jiang","year":"2024","journal-title":"Cell Death Discov"},{"issue":"9","key":"2025122309511278100_bib27","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1172\/JCI85795","article-title":"Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma","volume":"126","author":"Cardenas","year":"2016","journal-title":"J Clin Invest"},{"issue":"17","key":"2025122309511278100_bib28","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2025122309511278100_bib29","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025122309511278100_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"S3","key":"2025122309511278100_bib31","first-page":"PB2331","article-title":"An ongoing first-in-human phase 1 trial of Nx-5948, an oral Bruton\u2019s tyrosine kinase (Btk) degrader, in patients with relapsed\/refractory B cell malignancies [abstract]","volume":"7","author":"Linton","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 16","key":"2025122309511278100_bib32","doi-asserted-by":"crossref","first-page":"TPS7581","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7581","article-title":"A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies","volume":"40","author":"Mato","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025122309511278100_bib33","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2024-210951","article-title":"BMS-986458 a potential first-in-class, highly selective, potent and well tolerated BCL6 ligand directed degrader (LDD) demonstrates multi-modal anti-tumor efficacy for the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"144","author":"Groocock","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025122309511278100_bib34","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2025122309511278100_bib35","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2024-210591","article-title":"Novel insights into SOX11 modulation of BCR signaling and targeting of BTK resistance","volume":"144","author":"Dutta","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6267\/2474220\/blooda_adv-2025-016801-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6267\/2474220\/blooda_adv-2025-016801-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:51:21Z","timestamp":1766501481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6267\/546864\/SOX11-modulates-BCR-signaling-through-the-PAX5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":35,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016801","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,23]]}}}